CArdioSurgEry Atrial Fibrillation Register
Launched by STIFTUNG INSTITUT FUER HERZINFARKTFORSCHUNG · Mar 21, 2017
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The CArdioSurgEry Atrial Fibrillation Register, also known as CASE AF, is a clinical trial that aims to understand how patients with atrial fibrillation are treated when they undergo a specific heart surgery called cardiac surgical ablation. Atrial fibrillation is a condition where the heart beats irregularly, and this trial wants to gather information about the care these patients receive.
To participate in the trial, individuals must be between the ages of 65 and 74 and have been diagnosed with atrial fibrillation that is being treated with cardiac surgical ablation. If someone decides not to participate, that is completely fine, and they will not be included in the study. Those who join can expect to contribute to important research that could help improve treatment for others with this condition in the future. The trial is currently recruiting participants, and it welcomes individuals of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Atrial fibrilation
- • Treated by cardiac surgical ablation
- Exclusion Criteria:
- • Patient denies participation
About Stiftung Institut Fuer Herzinfarktforschung
The Stiftung Institut für Herzinfarktforschung is a leading clinical research organization dedicated to advancing cardiovascular medicine through innovative research and development. With a strong focus on heart attack prevention, diagnosis, and treatment, the institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials. Their commitment to scientific excellence and patient-centered approaches aims to translate groundbreaking findings into effective therapeutic interventions, ultimately enhancing patient outcomes in cardiovascular health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munchen, Bayern, Germany
Bad Rothenfelde, Nrw, Germany
Hamburg, , Germany
Patients applied
Trial Officials
Thorsten Hanke, MD
Principal Investigator
Asklepios Hamburg Harburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials